Login to Your Account

Ligand Sells More Products: $205M For Cancer Portfolio

By Randall Osborne

Monday, September 11, 2006
Ligand Pharmaceuticals Inc. has followed its sale of Avinza rights for $265 million to King Pharmaceuticals Inc. by offloading three more drugs - the rest of the firm's commercial operations - to Eisai Co. Ltd. for $205 million plus royalties, in what Ligand called an ongoing "shareholder value maximization process." (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription